SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing.

doi:10.1136/bcr-2023-255255

Article

SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing.

BMJ case reports - 9 Dec 2023

Seth-Smith Helena, Vesenbeckh Silvan, Egli Adrian, Ott Sebastian

Abstract excerpt

The evolution of SARS-CoV-2 within immunocompromised hosts who fail to clear the virus over many months has been proposed as a route to the development of Variants of Concern (VoCs). We present a case of an immunocompromised male patient with a prolonged SARS-CoV-2 infection. During hospitalisation, 7 weeks after first diagnosis, his condition worsened to require continuous ventilation support. Resolution of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing.

Abstract excerpt

Topics

SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing.

Abstract excerpt

Topics

Related research